Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Oral Oncol. 2010 Oct 14;46(12):880–887. doi: 10.1016/j.oraloncology.2010.09.005

Figure 4. PGE2 secretion in HNSCC cells.

Figure 4

A. PGE2 secretion levels in NOK-SI, HN13, HN12, and OSCC3 cells. B. PGE2 secretion inhibition in OSCC3 and HN13 as representative cells treated with celecoxib and indomethacin for 24h. No differences were observed regarding the COX-2 selectivity of these drugs. Lower doses (1 and 10 μM) were able to inhibit PGE2 secretion (p<0.001). C. MTS viability curve. Drug doses able to inhibit PGE2 secretion had no biological effects in both HNSCC cells and in NOK-SI after 24h of treatment. Similar results were observed after treatment for longer periods of time (2 and 3 days, not shown). Only higher doses decreased cell viability.